A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal melanoma.
2025
Refining Melanoma Treatment With Biomarker-Driven Insights
Welcome back to the second episode of this discussion about biomarkers. The last time we were together, we discussed sensitivity and specificity and the importance of these two aspects in terms of biomarkers in melanoma. We also discussed what kind of characteristics an ideal biomarker would have [in order] for us to use it in a clinical practice.
Ipilimumab plus nivolumab ‘considered a cure’ long term for melanoma brain metastasis
The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%.
Surviving melanoma has a new genetic story
Australia has the highest incidence of melanoma in the world with one Aussie diagnosed every 30 minutes.1 Delve into the research led by Dr Sarah Ward aiming to unpack the genetic epidemiology of melanoma.